This week's medical aesthetics supply-chain roundup features LaserOptek's groundbreaking VASCURA589 vascular laser, DK Healthcare and Mediintech's AI-driven endoscopy system, and other key developments relevant to overseas buyers and distributors of aesthetic devices and diagnostic equipment.
LaserOptek unveils VASCURA589: world-first high-power 589nm solid-state vascular laser
LaserOptek (CEO Lee Chang-jin) officially launched VASCURA589, the world's first high-power 589nm solid-state vascular laser, at a premiere event in Seoul on June 13. The device uses proprietary KGW Raman laser technology to achieve a 589nm wavelength at clinically meaningful power, a challenge the global laser engineering industry had not solved for decades. The wavelength is highly absorbed by oxyhemoglobin, enabling selective treatment of vascular lesions such as port-wine stains, hemangiomas, telangiectasias, rosacea, and flushing. VASCURA589 supports a quasi-long pulse mode (0.5ms to 40ms) for gradual heat accumulation, pulse repetition rates up to 10Hz, multiple spot sizes, and a CSC cooling system for epidermal protection. The core KGW Raman laser technology has been published in Applied Sciences (MDPI) and patented. The device was developed with support from the Ministry of SMEs and Startups, marking a milestone in reducing reliance on imported vascular lasers.
Market signal: vascular lesion laser market projected to reach $3.6B by 2033
According to Verified Reports 2025 data, the global vascular lesion treatment laser market was valued at approximately $1.94 billion in 2025 and is expected to grow at a CAGR of 8.1% to reach about $3.6 billion by 2033. LaserOptek aims to leverage VASCURA589 to strengthen its portfolio and accelerate global market entry.
DK Healthcare and Mediintech launch world-first motorized AI endoscopy system
DK Healthcare (CEO Lee Jun-hyuk) and Mediintech (CEO Lee Chi-won) signed a strategic MOU and officially launched the INTION S and INTION S AI systems at IDEN 2026. INTION S is the world's first motorized endoscopy system, replacing the mechanical operation method used for 55 years. It reduces control unit weight from 610g to 350g (over 40%) and wheel operation force by up to 85%, with clinical trials confirming reduced physical fatigue and workload for practitioners. The system provides FHD high-resolution imaging and motorized air/water/suction functions with real-time status visualization. It adopts the same button layout as conventional endoscopes and supports customizable function buttons for easy transition. A multicenter clinical trial at five institutions including Seoul National University Hospital demonstrated non-inferiority, published in Nature Scientific Reports. The learning curve is approximately two days (3-5 cases per day) for gastroscopy. INTION S AI includes lesion detection/classification and anomaly detection solutions. In retrospective trials, gastric cancer detection showed 96.33% sensitivity and 99.39% specificity for malignant lesions, and 97.67% sensitivity and 97.49% specificity for benign lesions. Three AI-assisted procedure solutions (EndoPilot, EndoTrack, EndoResect) have received regulatory approval and were demonstrated at IDEN 2026.
What buyers should watch: distribution and market strategy
DK Healthcare, leveraging 40 years of healthcare distribution experience and a nationwide branch network, will supply Mediintech's motorized AI endoscopy systems to domestic medical institutions. The companies plan to maintain consistent brand messaging and market strategy at major conferences to build market recognition.
Noolee presents AI blood analysis research at EHA 2026
Noolee (CEO Im Chan-yang) presented research on its AI-based blood analysis solution miLab BCM at the European Hematology Association (EHA) 2026 congress in Stockholm, Sweden. The study, conducted by Asan Medical Center, compared miLab BCM with automated hematology analyzers and expert microscopy. Results showed correlation coefficients above 0.97 for CBC parameters (RBC, Hgb, Hct) and higher concordance with expert readings for lymphocyte and monocyte analysis. For blast screening, miLab BCM achieved 96% negative predictive value (NPV), demonstrating its potential as a screening tool. Noolee's booth attracted visitors from over 30 countries, including Germany, Italy, Spain, Romania, Hungary, and Greece. The company plans to pursue product evaluations and clinical collaborations in key European markets.
DRGEM trains biomedical engineers from nine developing countries
DRGEM (CEO Park Jung-byung) conducted a specialized training program on June 12 at its Gimcheon plant for 12 biomedical engineers from nine countries (Ghana, Uganda, Egypt, Tanzania, Mongolia, Sri Lanka, Indonesia, Uzbekistan, Cambodia) under the KOFIH Lee Jong-wook Fellowship. Participants received hands-on training on X-ray equipment maintenance, operation management, and service parts supply, and toured DRGEM's manufacturing facilities. CEO Park emphasized the company's commitment to global medical infrastructure development through education and international cooperation.
Pharos iBio secures ODD from FDA, EMA for rare disease drug
Pharos iBio has obtained Orphan Drug Designation (ODD) from the U.S. FDA and the European Medicines Agency (EMA) for a rare disease treatment, preparing for commercialization. The company plans to expand technology transfer and joint research discussions with global big pharma.
MEMO Q Solution's wearable ECG patch receives FDA 510(k) clearance
MEMO Patch M, the core of the MEMO Q Solution ultra-small wearable electrocardiogram, has received FDA 510(k) clearance.
Source: Read the original report | Published: June 15, 2026